Two-year efficacy for Januvia plus metformin

At the 44th annual meeting of the European Association for the Study of Diabetes, in Rome, Italy, US drug major Merck & Co presented data showing that initial therapy with Januvia (sitagliptin) and metformin showed sustained two-year efficacy.

The mean A1C reductions from baseline in this study were 1.8% at one year (n=153) in patients treated with Januvia 50mg plus metformin 1,000mg twice-daily. In the extension trial at two years, the mean A1C reduction was 1.7% (n=105; baseline A1C of 8.6%) for this group.

Additionally, mean A1C reductions from baseline were 1.4% (at one year, n=147 and two years, n=96) in patients treated with Januvia 50mg/metformin 500 mg twice daily, 1.3% (at one year, n=134 and two years, n=87) in subjects metformin 1,000mg twice daily, 1.0% (at one year, n=117) and 1.1% (at two years, n=64) in people given metformin 500mg twice daily. For those on Januvia, there was a 0.8% reduction in A1C levels from baseline at one year and a 1.2% reduction from baseline at two years.